The weekly litigation news digest is live. Subscribe now

IP Verse

Immunogenic Composition - EP3138916

The patent EP3138916 was granted to Glaxosmithkline on Jun 19, 2019. The application was filed on May 25, 2012 under application number EP16193340A. The patent is currently recorded with a legal status of "Revoked".

EP3138916

GLAXOSMITHKLINE
Application Number
EP16193340A
Filing Date
May 25, 2012
Status
Revoked
Oct 27, 2023
Publication Date
Jun 19, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
VALNEVA AUSTRIAMar 16, 2020SCRIPTADMISSIBLE
VALNEVA AUSTRIAMar 16, 2020SCRIPT INTELLECTUALADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS4235877
DESCRIPTIONUS4751180
DESCRIPTIONUS4935233
DESCRIPTIONWO0061762
DESCRIPTIONWO0173030
DESCRIPTIONWO9612802
OPPOSITIONEP2753352
OPPOSITIONWO0061762
OPPOSITIONWO2010017383
OPPOSITIONWO2011060431
SEARCHWO0061762
SEARCHWO2010017383

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents